Elevated Plasma Factor VIII and D-Dimer Levels as Predictors of Poor Outcomes of Thrombosis in Children

2004 ◽  
Vol 351 (11) ◽  
pp. 1081-1088 ◽  
Author(s):  
Neil A. Goldenberg ◽  
R. Knapp-Clevenger ◽  
Marilyn J. Manco-Johnson
Keyword(s):  
Factor Viii ◽  
Elevated Plasma ◽  
Plasma Factor ◽  
Poor Outcomes ◽  
D Dimer

scholarly journals Elevated plasma factor VIII and d-dimer levels as predictors of poor outcome of thrombosis in children

2005 ◽  
Vol 41 (1) ◽  
pp. 176 ◽  
Author(s):  
NA Goldenberg ◽  
R Knapp-Clevenger ◽  
MJ Manco-Johnson
Keyword(s):  
Factor Viii ◽  
Elevated Plasma ◽  
Poor Outcome ◽  
Plasma Factor ◽  
D Dimer

Thrombotic stroke associated with elevated plasma factor VIII

1980 ◽  
Vol 8 (4) ◽  
pp. 435-437 ◽  
Author(s):  
Kenneth S. Kosik ◽  
Bruce Furie
Keyword(s):  
Factor Viii ◽  
Elevated Plasma ◽  
Plasma Factor

Factor VIII expression in liver disease

2004 ◽  
Vol 91 (02) ◽  
pp. 267-275 ◽  
Author(s):  
Martine Hollestelle ◽  
Hendrika Geertzen ◽  
Irene Straatsburg ◽  
Thomas van Gulik ◽  
Jan van Mourik
Keyword(s):  
Liver Cirrhosis ◽  
Liver Disease ◽  
Factor Viii ◽  
Rna Extraction ◽  
Control Group ◽  
Mrna Levels ◽  
Protein Distribution ◽  
Elevated Plasma ◽  
Cirrhotic Tissue ◽  
Plasma Factor

SummaryLiver disease is associated with markedly elevated plasma factor VIII (FVIII) levels, whereas the synthesis of many other coagulation factors and proteins is reduced. In order to define the mechanism of FVIII increase, we have determined the expression levels of FVIII, both at mRNA and protein level, in patients with liver disease who underwent partial liver resection. In addition, the expression of von Willebrand factor (VWF) and low density lipoprotein receptor-related protein (LRP), proteins known for their ability to modulate FVIII plasma levels, were examined. Tissue samples for RNA extraction were obtained from 4 patients with cirrhosis, 9 patients with liver failure without cirrhosis and 6 patients with liver metastasis of a colon or rectum carcinoma (control group). In patients with liver cirrhosis hepatic FVIII and LRP mRNA levels were significantly lower than controls (p ≤ 0.010), while VWF mRNA was significantly higher (p ≤ 0.050). Immunohistochemical analysis revealed that cellular VWF protein distribution was also increased in cirrhotic livers compared to liver tissue from patients with non-cirrhotic liver disease. In cirrhotic tissue enlarged portal veins appeared to overgrow FVIII producing sinusoidal endothelial cells. Similarly, the number of LRP-producing cells appeared to be lower in cirrhotic tissue than in controls. The plasma concentration of both FVIII and VWF was significantly higher in patients with cirrhosis than control subjects (p = 0.038 and 0.010 respectively). These results demonstrate that elevated plasma FVIII levels in liver cirrhosis are associated with increased hepatic biosynthesis of VWF and decreased expression of LRP, rather than increased FVIII synthesis.

Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor

1983 ◽  
Vol 74 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Nancy W. Stead ◽  
Kenneth A. Bauer ◽  
Thomas R. Kinney ◽  
James G. Lewis ◽  
Elizabeth E. Campbell ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Factor Viii ◽  
Plasminogen Activator ◽  
Elevated Plasma ◽  
Plasma Factor ◽  
Von Willebrand’S Factor

scholarly journals The Effect of Venous Thromboembolism on Survival of Cancer Patients and its Relationship with Serum Levels of Factor VIII and Vascular Endothelial Growth Factor: A Prospective Matched-Paired Study

2006 ◽  
Vol 21 (4) ◽  
pp. 206-210 ◽  
Author(s):  
M. Dogan ◽  
A. Demirkazik ◽  
N. Konuk ◽  
B. Yalcin ◽  
A. Buyukcelik ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Venous Thromboembolism ◽  
Growth Factor ◽  
Factor Viii ◽  
Cancer Patients ◽  
Control Group ◽  
Vascular Endothelial ◽  
Plasma Factor ◽  
Endothelial Growth Factor ◽  
D Dimer

Background Venous thromboembolism (VT) increases mortality and morbidity in cancer patients. The primary aim of this study was to evaluate the effect of VT on the survival of cancer patients and its relationship with serum vascular endothelial growth factor (VEGF) and plasma factor VIII levels. Patients and methods Eighty-two patients with locally advanced or metastatic cancer were included in this study between September 2001 and March 2004, and 31 of them had VT. Fifty-one matched-paired cancer patients without VT were prospectively selected as a control group in the same period. Criteria for the selection of control group patients were having the same malignancy, stage, metastatic site, performance status and age (±5 years) as patients in the VT group. Results Plasma factor VIII and serum D-dimer levels in the VT group were significantly higher than those in the control group (p=0.030 and p=0.016, respectively). However, mean serum VEGF levels were similar in both groups (p=0.199). In the VT group, the median survival of patients who had higher serum VEGF levels (>150 pg/mL) was significantly shorter than that of patients in the same group with lower serum VEGF levels (p=0.005). The median survival of the VT group was 14 months, whereas it was 25 months in the control group (p=0.199). Conclusion There was a worse prognostic trend for cancer patients with VT. Nevertheless, the difference in survival was not statistically significant between the groups. Plasma factor VIII and serum D-dimer levels might have prognostic value in cancer patients with VT. Cancer patients with VT and higher serum VEGF levels had a significantly poorer prognosis.

Sign in / Sign up

Export Citation Format

Share Document